Clinical Trials
146 trialsChemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer
Peking Union Medical College Hospital
Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
Sun Yat-sen University
SNMM
Eye & ENT Hospital of Fudan University
Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma
American University of Beirut Medical Center
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
Case Comprehensive Cancer Center
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
Loyola University
DIPG
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
LARCT-US
Uppsala University
Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
First Affiliated Hospital of Guangxi Medical University
IMPROVE
Fudan University
Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma
Sun Yat-sen University
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Second Affiliated Hospital of Soochow University
SBRT Plus vNKT for Pancreatic Cancer
Changhai Hospital
HIST-RIC
Institut Paoli-Calmettes
PANDORA
AUSL Romagna Rimini
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
Salah Azaïz Cancer Institute
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer
Sun Yat-sen University
ORATOR
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma
China Three Gorges University, Yichang, China
Radiotherapy Combined With Realgar-Indigo Naturalis Formula (RIF) in the Treatment of Rhabdomyosarcoma(RMS) in Children
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
West China Hospital
Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma
Ruijin Hospital
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)
Second Affiliated Hospital of Soochow University
Nivolumab+Ipilimumab+RT in MSS mCRC
Massachusetts General Hospital
iCSDeR
Hubei Cancer Hospital
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
Peking Union Medical College Hospital
Radiotherapy in Combination With Sintilimab,GM-CSF and Fruquintinib in Patients With MSS mCRC
The First Affiliated Hospital of Xiamen University
TONIC
The Netherlands Cancer Institute
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Fudan University
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
Zhejiang Cancer Hospital
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
ChineseAMS
ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)
Second Affiliated Hospital of Soochow University
A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression
Sun Yat-sen University
Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
F&C
Tianjin Medical University Cancer Institute and Hospital
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer
Accuray Incorporated
The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Radiation Therapy in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Grade II or Grade III Meningioma
European Organisation for Research and Treatment of Cancer - EORTC
QRT-SOGUG
Spanish Oncology Genito-Urinary Group
Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma
Peking Union Medical College Hospital
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Tianjin Medical University Cancer Institute and Hospital
Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
Sichuan Cancer Hospital and Research Institute
Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study of DC Vaccination Against Glioblastoma
Huashan Hospital
Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study
Shanghai Cancer Hospital, China